APOA1 and pancreatic ductal adenocarcinoma: Lin et al. revealed that apolipoprotein A-I and transferrin were significant different between CA19-9-negative pancreatic ductal adenocarcinoma and healthy controls through the method of ITRAQ-based quantitative proteomics (27) and suggested that they might be potential biomarkers to be validated in a larger sample cohort.